Skip to main content

Table 2 Study 2 design and efficacy of oral moxidectin against Dirofilaria immitis (JYD-34, ZoeLA)

From: Preventive efficacy of oral moxidectin at various doses and dosage regimens against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs

Strain

Groupa (n = 5)

Treatmentb

Dosage (µg/kg)

Days of treatment

No. of dogs with worms

Adult D. immitis worm countsc

Individual worm counts

Geometric meand

% reductione

JYD-34

T01

Placebo

na

0, 28, 56

5 of 5

5, 23, 27, 33, 33

20.6f

–

T03

Moxidectin

24

0, 28, 56

1 of 5

2

0.2g

98.8

T04

Moxidectin

40

0, 28, 56

0 of 5

0

0g

100.0

T05

Moxidectin

60

0, 28, 56

0 of 5

0

0g

100.0

ZoeLA

T02

Placebo

na

0, 28, 56

5 of 5

25, 26, 31, 37, 38

30.9f

–

T06

Moxidectin

3

0

5 of 5

11, 13, 17, 19, 25

20.0g

44.4

T07

Moxidectin

24

0, 28, 56

1 of 5

1

0.1h

99.5

T08

Moxidectin

40

0, 28, 56

1 of 5

1

0.1h

99.5

T09

Moxidectin

60

0

5 of 5

1, 1, 6, 6, 10

3.6i

88.2

T10

Moxidectin

60

0, 28, 56

0 of 5

0

0h

100

  1. aAll dogs were inoculated with 50 D. immitis L3 at Day -30. Groups T01 and T03–T05 received the JYD-34 strain; Groups T02 and T06–T10 received the ZoeLA strain
  2. bMoxidectin administered as ProHeart® tablets shaved to deliver the correct dose
  3. cAll dogs were necropsied for recovery and enumeration of adult heartworms on Day 103 (133 days post-inoculation)
  4. dMeans with different superscript letters (f–i) are significantly different within each strain t(34) = 2.33, P = 0.0259 for T02 vs T06; 7.36 ≤ t(34) ≤ 13.21, P < 0.0001 for all other significant differences
  5. ePercentage reduction is compared to T01 for Groups T03–T05 and compared to T02 for Groups T06–T10
  6. Abbreviation: na, not applicable